越南的保健并购市场于2025年猛增, 由私人股本投资引领, 成为东南亚最活跃的市场。 Vietnam's healthcare M&A market surged in 2025, led by private equity investments in established providers, making it Southeast Asia’s most active market.

越南的保健合并和收购市场在私人股权和机构投资者的推动下,于2025年猛增,以肿瘤学和心脏病学等专业的既定多地点提供者为目标。 Vietnam’s healthcare M&A market surged in 2025, driven by private equity and institutional investors targeting established, multi-location providers in specialties like oncology and cardiology. 关键交易,包括阿瑞斯对美德拉特克(Medlatec)和夸德里雅资本(Quadria Capital)的投资,反映出全球对越南经认证的、可供出口的医疗保健平台的兴趣日益浓厚。 Key deals, including Ares’s investment in Medlatec and Quadria Capital’s acquisition of Tam Tri Medical, reflected growing global interest in Vietnam’s certified, export-ready healthcare platforms. 活动集中在河内和胡志明市，次级城市逐渐获得关注。 Activity concentrated in Hanoi and Ho Chi Minh City, with secondary cities gaining traction. 通过 " 螺栓式收购 " 扩大PE支持的公司,而2020-2022年的投资则接近出口窗口,有可能设定新的估价基准。 PE-backed firms expanded through bolt-on acquisitions, while investments from 2020–2022 approached exit windows, potentially setting new valuation benchmarks. 这个部门的势头在强大的利润和区域贸易优势的支持下,巩固了越南作为东南亚最活跃的保健并购市场的地位。 The sector’s momentum, supported by strong margins and regional trade advantages, solidified Vietnam’s status as Southeast Asia’s most active healthcare M&A market.